First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs HS 10241 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Atridia; Jiangsu Hengrui Medicine Co.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2016 Status changed from not yet recruiting to recruiting.
- 13 Jul 2016 Planned number of patients changed from 27 to 36.